Patent: 6,362,213
✉ Email this page to a colleague
Summary for Patent: 6,362,213
Title: | Cyclic AMP-specific phosphodiesterase inhibitors |
Abstract: | Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed. |
Inventor(s): | Gaudino; John J. (Boulder, CO) |
Assignee: | ICOS Corporation (Bothell, WA) |
Application Number: | 09/737,987 |
Patent Claims: | see list of patent claims |
Details for Patent 6,362,213
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2019-12-23 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2019-12-23 |
Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 05/27/1999 | ⤷ Try a Trial | 2019-12-23 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 09/27/2004 | ⤷ Try a Trial | 2019-12-23 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | 02/01/2007 | ⤷ Try a Trial | 2019-12-23 |
Immunex Corporation | ENBREL MINI | etanercept | Injection | 103795 | 09/14/2017 | ⤷ Try a Trial | 2019-12-23 |
Immunex Corporation | ENBREL | etanercept | Injection | 103795 | ⤷ Try a Trial | 2019-12-23 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |